PMA device
Edwards SAPIEN XT Transcatheter Heart Valve
Edwards Lifesciences, LLC · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Jun 16, 2014, newest Oct 27, 2020Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
12
PMA pathway
Device trials
19
Naming "SAPIEN XT"
MAUDE reports
2,777
Brand "SAPIEN XT", since 2015
PubMed studies
561
Mentioning "SAPIEN XT"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Edwards SAPIEN XT Transcatheter Heart Valve
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 12 decisions filed under this name.
- Edwards SAPIEN XT Transcatheter Heart ValvePMA supplement
P130009-S109 · Decided Oct 27, 2020 · 172 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
- Edwards SAPIEN XT Transcatheter Heart ValvePMA supplement
P130009-S105 · Decided Apr 10, 2020 · 144 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
- Edwards Sapien XT Transcatheter Heart ValvePMA supplement
P130009-S101 · Decided Nov 4, 2019 · 47 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
3 more FDA decisions with a free account
Older decisions: P130009-S057, P130009-S053, P130009-S037, P130009-S034, P130009-S002, P130009
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "SAPIEN XT", any status and sponsor, newest update first.
Edwards LifesciencesPublic (EW)
NCT02987387 · 57 participants · Start Jul 17, 2017 · Primary completion Aug 9, 2021
Device: SAPIEN XT THV · For: Pulmonary Valve Insufficiency; Pulmonary Valve Stenosis; Heart Defects, Congenital and 3 more
Sites: Birmingham, Alabama; Aurora, Colorado; Washington D.C., District of Columbia · 12 sites in all
Henry Ford Health SystemAcademic, hospital or other
NCT02339974 · 15 participants · Start Jan 2015 · Primary completion Dec 2024
Device: Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava · For: Tricuspid Regurgitation
Sites: Detroit, Michigan
- PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High RiskPivotal-lookingCompleted
Edwards LifesciencesPublic (EW)
NCT01314313 · 2,032 participants · Start Mar 2011 · Primary completion Jan 2016
Device: TAVR Implantation with SAPIEN XT; SAVR Implantation · For: Symptomatic Severe Aortic Stenosis
Sites: Little Rock, Arkansas; La Jolla, California; Los Angeles, California · 57 sites in all
16 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SAPIEN XT", and for the whole product code for context.
This brand
2,777 reports: 70 malfunction, 2,524 injury, 180 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
2015691-2026-19708 · Received Oct 26, 2026 · Event dated Oct 2, 2026
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Device problem as coded: Unspecified Valve Regurgitation
Patient problem as coded: Insufficient Information
2015691-2026-19724 · Received Oct 26, 2026 · Event dated Oct 7, 2026
Device type: Pulmonary Valve Prosthesis Percutaneously Delivered (NPV)
Device problem as coded: Degraded
Patient problem as coded: Insufficient Information
2015691-2026-19412 · Received Oct 14, 2026 · Event dated Sep 28, 2026
Device type: Prosthesis, Mitral Valve, Percutaneously Delivered (NPU)
Device problem as coded: Calcified
Patient problem as coded: Dyspnea; Heart Failure/Congestive Heart Failure
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SAPIEN XT"[tiab]. The summary above synthesizes these.
- Trans-apical systemic tricuspid valve-in-ring replacement.
Ghobrial J, Reemtsen B, Levi DS, et al. · Catheter Cardiovasc Interv · 2019Case Reports, Video-Audio Media
- Sapien 3 versus Sapien XT prosthetic valves in transcatheter aortic valve implantation: A meta-analysis.
Ando T, Briasoulis A, Holmes AA, et al. · Int J Cardiol · 2016Comparative Study, Meta-Analysis
- Good news and bad news.
Hagler DJ · Catheter Cardiovasc Interv · 2016Editorial, Comment
- [Percutaneous treatment of the pulmonary valve].
Guerin P, Fresse KW, Razafimahatratra O · Ann Cardiol Angeiol (Paris) · 2019Review
- Long-term outcomes of balloon-expandable transcatheter aortic valve replacement in Japanese patients.
Fuku Y, Goto T, Ikuta A, et al. · J Cardiol · 2023
- Percutaneous Pulmonary Valve Replacement: What a Difference a Day Makes.
Horlick EM, Haas NA · J Am Coll Cardiol · 2020Editorial, Comment
- Successful SAPIEN 3 Implantation for Structural Valve Deterioration of a SAPIEN XT.
Imaoka T, Naganuma T, Nakamura S · Circ J · 2023
- Transcatheter Valve-in-Valve: A Cautionary Tale.
Luc JGY, Shanks M, Tyrrell BD, et al. · Ann Thorac Surg · 2016Case Reports
- Edwards valve-in-valve implantation in tricuspid position.
Álvarez-Fuente M, Haas NA, Del Cerro MJ · Cardiol Young · 2017Case Reports
- Edwards SAPIEN XT transcatheter pulmonary valve implantation: 5-year follow-up in a French Registry.
Le Ruz R, Plessis J, Houeijeh A, et al. · Catheter Cardiovasc Interv · 2021
- The SAPIEN-XT and SAPIEN-3 Valves: How to Implant and Obtain the Best Outcomes.
Halapas A, Chrissoheris M, Bouboulis N, et al. · Hellenic J Cardiol · 2015Review
- Sapien 3 versus Sapien XT Balloon-expanding Valve for Transcatheter Aortic Valve Replacement: Improved Immediate and Late Outcomes at the Expense of Smaller Effective Orifice Area.
Ko YG · Korean Circ J · 2020Editorial
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Medtronic CoreValve Evolut R SystemMedtronic, Inc. · PMA 2022
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
- LOTUS Edge Valve SystemBoston Scientific Corporation · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.